The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Anti-spasticity agents for multiple sclerosis
Open accessAbstract
BACKGROUND: Spasticity is a common problem in MS patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available. OBJECTIVES: To assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis (MS) patients. SEARCH STRATEGY: Randomised controlled trials (RCTs) of anti-spasticity agents were identified using MEDLINE, EMBASE, bibliographies of relevant articles, personal communication, manual searches of relevant journals and information from drug companies. SELECTION CRITERIA: Double-blind, randomised controlled trials (either placebo-controlled or comparative studies) of at least seven days duration. DATA COLLECTION AND ANALYSIS: Two independent reviewers extracted data and the findings of the trials were summarised. Missing data were collected by correspondence with principal investigators. A meta-analysis was not performed due to the inadequacy of outcome measures and methodological problems with the studies reviewed. MAIN RESULTS: Twenty-three placebo-controlled studies (using baclofen, dantrolene, tizanidine, botulinum toxin, vigabatrin, prazepam and threonine) and thirteen comparative studies met the selection criteria. Only thirteen of these studies used the Ashworth scale, of which only three of the six placebo-controlled trials and none of the seven comparative studies showed a statistically significant difference between test drugs. Spasms, other symptoms and overall impressions were only assessed using unvalidated scores and results of functional assessments were inconclusive. REVIEWER'S CONCLUSIONS: The absolute and comparative efficacy and tolerability of anti-spasticity agents in multiple sclerosis is poorly documented and no recommendations can be made to guide prescribing. The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS.
Ashworth, B. (1964) · PubMed · Cited by 1,475
Merkies, I. S. J., & Kieseier, B. C. (2016) · European Neurology · doi:10.1159/000445347 · Cited by 869
Pandyan, A. D., Johnson, G. R., Price, C. I. M., Curless, R. H., Barnes, M. P., & Rodgers, H. (1999) · Clinical Rehabilitation · doi:10.1191/026921599677595404 · Cited by 833
Intrathecal Baclofen for Severe Spinal Spasticity
Penn, R. D., Savoy, S. M., Corcos, D., Latash, M., Gottlieb, G., Parke, B., & Kroin, J. S. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906083202303 · Cited by 754
Measurement In Neurological Rehabilitation
Harms, M. (1992) · Physiotherapy · doi:10.1016/s0031-9406(10)60484-1 · Cited by 530
Wade, D. T., Robson, P., House, H., Makela, P., & Aram, J. (2003) · Clinical Rehabilitation · doi:10.1191/0269215503cr581oa · Cited by 441
Treatment of spasticity with botulinum toxin: A double‐blind study
Snow, B. J., Tsui, J. K. C., Bhatt, M. H., Varelas, M., Hashimoto, S. A., & Calne, D. B. (1990) · Annals of Neurology · doi:10.1002/ana.410280407 · Cited by 414
Measurement in neurological rehabilitation.
Wade, D. T. (1992) · PubMed · Cited by 351
CONTINUOUS INTRATHECAL BACLOFEN FOR SEVERE SPASTICITY
PENN, R. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90228-4 · Cited by 308
Intrathecal baclofen for spasticity of spinal origin: seven years of experience
Penn, R. D. (1992) · Journal of Neurosurgery · doi:10.3171/jns.1992.77.2.0236 · Cited by 279
Hyman, N. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.707 · Cited by 248
Morita, H. (2001) · Brain · doi:10.1093/brain/124.4.826 · Cited by 239
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Killestein, J., Hoogervorst, E. L. J., Reif, M., Kalkers, N. F., van Loenen, A. C., Staats, P. G. M., Gorter, R. W., Uitdehaag, B. M. J., & Polman, C. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1404 · Cited by 209
Botulinum toxin A for spasticity, muscle spasms, and rigidity
Grazko, M. A., Polo, K. B., & Jabbari, B. (1995) · Neurology · doi:10.1212/wnl.45.4.712 · Cited by 207
Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Russo, E. B. (2003) · Neurology · doi:10.1212/wnl.60.4.729-a · Cited by 184
Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.
Ochs, G., Struppler, A., Meyerson, B. A., Linderoth, B., Gybels, J., Gardner, B. P., Teddy, P., Jamous, A., & Weinmann, P. (1989) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.8.933 · Cited by 168
Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis
Ungerleider, J. T., Andyrsiak, T., Fairbanks, L., Ellison, G. W., & Myers, L. W. (1988) · Advances in Alcohol & Substance Abuse · doi:10.1300/j251v07n01_04 · Cited by 165
Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial
Cutter, N. C., Scott, D. D., Johnson, J. C., & Whiteneck, G. (2000) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(00)90135-7 · Cited by 160
Treatment of Human Spasticity with Δ9‐Tetrahydrocannabinol
Petro, D. J., & Ellenberger, C. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02621.x · Cited by 154
Rodgers, M. M., Mulcare, J. A., King, D. L., Mathews, T., Gupta, S., & Glaser, R. M. (1999) · PubMed · Cited by 149
Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury
Loubser, P. G., Narayan, R. K., Sandin, K. J., Donovan, W. H., & Russell, K. D. (1991) · Spinal Cord · doi:10.1038/sc.1991.7 · Cited by 146
Effect of cannabinoids on spasticity and ataxia in multiple sclerosis
Meinck, H. ‐., Sch�nle, P. W., & Conrad, B. (1989) · Journal of Neurology · doi:10.1007/bf00314410 · Cited by 131
Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis
Mueller, M. E., Gruenthal, M., Olson, W. L., & Olson, W. H. (1997) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(97)90168-4 · Cited by 121
4-Aminopyridine in the Treatment of Patients With Multiple Sclerosis
Polman, C. H. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540150090022 · Cited by 121
Baclofen in the Treatment of Spasticity
Hudgson, P., & Weightman, D. (1971) · BMJ · doi:10.1136/bmj.4.5778.15 · Cited by 121
Nance, P. W., Schryvers, O. I., Schmidt, B. J., et al. (1995) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100040452 · Cited by 105
Determinants of Muscle Function in the Spastic Lower Extremity
Perry, J. (1993) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-199303000-00003 · Cited by 105
Sachais, B. A. (1977) · Archives of Neurology · doi:10.1001/archneur.1977.00500190056008 · Cited by 105
Short-term effects of intrathecal baclofen in spasticity
Latash, M. L., Penn, R. D., Corcos, D. M., & Gottlieb, G. L. (1989) · Experimental Neurology · doi:10.1016/0014-4886(89)90078-2 · Cited by 100
An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions
DUNCAN, G. W., Shahani, B. T., & Young, R. R. (1976) · Neurology · doi:10.1212/wnl.26.5.441 · Cited by 97
Tizanidine Versus Baclofen in the Treatment of Spasticity in Patients with Multiple Sclerosis
Bass, B., Weinshenker, B. G., Rice, G. P., et al. (1988) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100027104 · Cited by 90
The effects of the GABA agonist, baclofen, on sleep and breathing
Finnimore, A. J., Roebuck, M. M., Sajkov, D., & McEvoy, R. D. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08020230 · Cited by 86
A comparison of baclofen and diazepam in the treatment of spasticity
Cartlidge, N. E. F., Hudgson, P., & Weightman, D. (1974) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(74)90137-3 · Cited by 82
Smith, C. R., Birnbaum, G., Carter, J. L., et al. (1994) · PubMed · Cited by 75
Stien, R., Nordal, H. J., Oftedal, S., et al. (1987) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1987.tb07916.x · Cited by 72
Nance, P. W., Sheremata, W. A., LYNCH, S. G., Vollmer, T., Hudson, S., Francis, G., O'Connor, P. W., Cohen, J. A., Schapiro, R. T., Whitham, R. H., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550180049011 · Cited by 72
Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients
Hoogstraten, M. C., Ploeg, R. J., van den Burg, W., Vreeling, A., van Marle, S., & Minderhoud, J. M. (1988) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1988.tb05899.x · Cited by 71
Treatment of Spasticity with Tizanidine in Multiple Sclerosis
Lapierre, Y., Bouchard, S., Tansey, C. M., et al. (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100038026 · Cited by 70
Smith, C. R., LaRocca, N. G., Giesser, B. S., & Scheinberg, L. C. (1991) · Neurology · doi:10.1212/wnl.41.11.1829 · Cited by 69
The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients
ørsnes, G. B., Crone, C. G., Krarup, C., Petersen, N., & Nielsen, J. B. (2000) · Clinical Neurophysiology · doi:10.1016/s1388-2457(00)00352-7 · Cited by 66
Tizanidine in the treatment of spasticity
Newman, P. M., Nogués, M. A., Newman, P. K., et al. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf01061374 · Cited by 64
A DOUBLE-BLIND TRIAL WITH BACLOFEN (LIORESAL®) AND DIAZEPAM IN SPASTICITY DUE TO MULTIPLE SCLEROSIS
From, A., & Heltberg, A. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1975.tb01366.x · Cited by 63
Comparison of dantrolene sodium and diazepam in the treatment of spasticity.
Schmidt, R. T., Lee, R. H., & Spehlmann, R. (1976) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.39.4.350 · Cited by 61
The effect of dantrolene sodium on spasticity in multiple sclerosis
Gelenberg, A. J., & Poskanzer, D. C. (1973) · Neurology · doi:10.1212/wnl.23.12.1313 · Cited by 56
Eyssette, M., Rohmer, F., Serratrice, G., et al. (1988) · Current Medical Research and Opinion · doi:10.1185/03007998809111121 · Cited by 56
Bohannon, R. W. (1987) · Physical Therapy · doi:10.1093/ptj/67.5.659 · Cited by 56
Action of cyproheptadine in spastic paraparetic patients.
Barbeau, H., Richards, C. L., & Bédard, P. J. (1982) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.45.10.923 · Cited by 54
Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?
Jarrett, L. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.705 · Cited by 54
Smolenski, C., Muff, S., & Smolenski-Kautz, S. (1981) · PubMed · Cited by 52
Whitehead, A., & Jones, N. M. B. (1994) · Statistics in Medicine · doi:10.1002/sim.4780132313 · Cited by 51
The Use of Baclofen in Treatment of Spasticity in Multiple Sclerosis
Sawa, G. M., & Paty, D. W. (1979) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100023994 · Cited by 47
Roussan, M. S., Terrence, C. F., & Fromm, G. H. (1985) · PubMed · Cited by 42
Marihuana as a therapeutic agent for muscle spasm or spasticity
Petro, D. J. (1980) · Psychosomatics · doi:10.1016/s0033-3182(80)73129-8 · Cited by 38
An Antispasticity Effect of Threonine in Multiple Sclerosis
Hauser, S. L., Doolittle, T. H., Lopez-Bresnahan, M. V., Shahani, B. T., Schoenfeld, D., Shih, V. E., Growdon, J. H., & Lehrich, J. R. (1992) · Archives of Neurology · doi:10.1001/archneur.1992.00530330045014 · Cited by 38
GABAPENTIN FOR RELIEF OF SPASTICITY ASSOCIATED WITH MULTIPLE SCLEROSIS1
Dunevsky, A., & Perel, A. B. (1998) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199809000-00020 · Cited by 32
Jerusalem, F. (1968) · PubMed · Cited by 28
A comparison of dantrolene sodium and diazepam in the treatment of spasticity
Glass, A., & Hannah, A. (1974) · Spinal Cord · doi:10.1038/sc.1974.27 · Cited by 25
[Experience using sinakten-retard in the treatment of muscular sclerosis].
Neretin, V. I., Va, K., & Ln, P. (1978) · PubMed · Cited by 24
Phenytoin and Chlorpromazine in the Treatment of Spasticity
COHAN, S. L., Raines, A., Panagakos, J., & Armitage, P. (1980) · Archives of Neurology · doi:10.1001/archneur.1980.00500550062008 · Cited by 20
Treatment of Spasticity in Multiple Sclerosis With Dantrolene
TOLOSA, E. S. (1975) · JAMA · doi:10.1001/jama.1975.03260100016002 · Cited by 19
Lioresal (baclofen) treatment of spasticity in multiple sclerosis.
Jv, B. (1975) · PubMed · Cited by 16
Mode of action of dantrolene sodium in spasticity
Mai, J., & Pedersen, E. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1979.tb02941.x · Cited by 12
Letter: Treatment of spasticity in multiple sclerosis with dantrolene
Tolosa, E. S. (1975) · JAMA · doi:10.1001/jama.233.10.1046b · Cited by 11
Lossius, R., Dietrichson, P., & Lunde, P. K. M. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1985.tb03187.x · Cited by 10
[Treatment of spasticity with botulinum toxin].
Kerty, E., & Stien, R. (1997) · PubMed · Cited by 10
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis
Collin, C., Davies, P., Mutiboko, I. K., Ratcliffe, S., & for the Sativex Spasticity in MS Study Group (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01639.x · Cited by 379
Chou, R., Peterson, K., & Helfand, M. (2004) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.05.002 · Cited by 375
Givon, U., Zeilig, G., & Achiron, A. (2009) · Gait & Posture · doi:10.1016/j.gaitpost.2008.07.011 · Cited by 314
Metadata
- Authors
- Shakespeare, D., Boggild, M., & Young, C. A.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2003-10-20
- Volume
- 2010
- Issue
- 1
- Pages
- CD001332-CD001332
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2158699108
- Cited by
- 271
- References
- 68
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.